Significant advance announced in treatment of cervical cancer
August 18, 2010 by admin · Leave a Comment
Research demonstrates that drug and radiotherapy treatment saves lives
A medical researcher at the University of Leicester has made a significant advance in the treatment of cervical cancer.
New target for treatment of ovarian cancer
August 15, 2010 by admin · Leave a Comment
A protein that plays a key role in regulating the onset of cell division has been identified as a potential target for the treatment of ovarian cancer. The research, published by Cell Press in the August issue of the journal Cancer Cell, provides evidence that combination therapies targeting different phases of the cell division cycle are highly desirable for optimal cancer treatment.
New drug reduces tumor size in women with advanced hereditary ovarian or breast cancer
August 10, 2010 by admin · Leave a Comment
Cedars-Sinai participates in international study suggesting that the underlying genetic weakness of cancer, not the organ of origin, is key to effective therapy
LOS ANGELES (Aug. 11, 2010) Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.
Initial trials on new ovarian cancer tests exhibit extremely high accuracy
August 10, 2010 by admin · Leave a Comment
Scientists at the Georgia Institute of Technology have attained very promising results on their initial investigations of a new test for ovarian cancer. Using a new technique involving mass spectrometry of a single drop of blood serum, the test correctly identified women with ovarian cancer in 100 percent of the patients tested. The results can be found online in the journal Cancer Epidemiology, Biomarkers, & Prevention Research.
Yale scientists discover new genetic marker of ovarian cancer risk
July 19, 2010 by admin · Leave a Comment
New Haven, Çonn. - A team of Yale researchers have identified a genetic marker that can help predict the risk of developing ovarian cancer, a hard to detect and often deadly form of cancer.
Reporting online in the July 20 edition of the journal Cancer Research, the team showed that a variant of the KRAS oncogene was present in 25 percent of all ovarian cancer patients. In addition, this variant was found in 61 percent of ovarian cancer patients with a family history of breast and ovarian cancer, suggesting that this marker may be a new marker of ovarian cancer risk for these families, said the researchers.
Protein inhibitor revives effect of chemotherapy for ovarian patients
July 5, 2010 by admin · Leave a Comment
Discovery provides new hope to cancer patients with few treatment options
PHOENIX, Ariz. July 6, 2010 Investigators at the Translational Genomics Research Institute (TGen) have discovered a way that may help ovarian cancer patients who no longer respond to conventional chemotherapy.
Late-stage ovarian cancer shows promise in two-drug phase I trial
June 8, 2010 by admin · Leave a Comment
INDIANAPOLIS — The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.
New treatment regimen shown effective against advanced ovarian cancer
June 5, 2010 by admin · Leave a Comment
Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center
CHICAGO (June 6, 2010) Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.
CA-125 change over time shows promise as screening tool for early detection of ovarian cancer
May 19, 2010 by admin · Leave a Comment
Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center Read more
PMH cancer researchers link ovarian hormone to breast stem cells growth
May 4, 2010 by admin · Leave a Comment
Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
Cancer researchers at Princess Margaret Hospital (PMH) have discovered that the ovarian hormone progesterone plays a pivotal role in altering breast stem cells, a finding that has important implications for breast cancer risk.
